E
Elizabeth J J Berm
Researcher at University of Groningen
Publications - 10
Citations - 267
Elizabeth J J Berm is an academic researcher from University of Groningen. The author has contributed to research in topics: Nortriptyline & Pharmacogenetics. The author has an hindex of 7, co-authored 10 publications receiving 223 citations.
Papers
More filters
Journal ArticleDOI
Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature
Elizabeth J J Berm,Margot de Looff,Bob Wilffert,Bob Wilffert,Cornelis Boersma,Lieven Annemans,Stefan Vegter,Job F M van Boven,Maarten J. Postma +8 more
TL;DR: It was found that only the minority of recent pharmacoeconomic evaluations assessed the intrinsic value of the PGx tests, which was mostly found to be a cost-effective or cost-saving strategy.
Journal ArticleDOI
A simple dried blood spot method for therapeutic drug monitoring of the tricyclic antidepressants amitriptyline, nortriptyline, imipramine, clomipramine, and their active metabolites using LC-MS/MS.
TL;DR: A fast and robust LC-MS/MS method was developed and analytically validated for simultaneous determination of ATP, NTP, IMP, DSP, CMP, and DCMP in DBS and a good correlation was found between patients plasma and DBS samples of ATP and DMCP, but not for CMP.
Journal ArticleDOI
Determination of venlafaxine and O-desmethylvenlafaxine in dried blood spots for TDM purposes, using LC-MS/MS.
TL;DR: A fast and robust LC-MS/MS method was developed and analytically validated for simultaneous determination of venlafaxine (VEN) and O-desmethylvenlafAXine (ODV) in DBS and applicable for TDM.
Journal ArticleDOI
Relation between CYP2D6 Genotype, Phenotype and Therapeutic Drug Concentrations among Nortriptyline and Venlafaxine Users in Old Age Psychiatry
TL;DR: Genotype information could be used as a valuable tool, in addition to therapeutic drug monitoring, to prevent supratherapeutic drug levels of nortriptyline or venlafaxine in elderly patients with a PM genotype.
Journal ArticleDOI
Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine : Study protocol for a pragmatic randomized controlled trial (CYSCEtrial)
Elizabeth J J Berm,Eelko Hak,Eelko Hak,Maarten J. Postma,Maarten J. Postma,Marjolein Boshuisen,Laura Breuning,Jacobus Brouwers,Ton Dhondt,Paul A. F. Jansen,Rob M. Kok,J. G. Maring,Rob J. van Marum,Rob J. van Marum,Hans Mulder,Richard C. Oude Voshaar,Arne J. Risselada,Harry Venema,Liesbeth Vleugel,Bob Wilffert,Bob Wilffert +20 more
TL;DR: Results of this trial will guide policy-making with regard to pharmacogenetic screening prior to treatment with nortriptyline or venlafaxine among older patients with depression.